Emergence of Dendritic Cells in the Myocardium after Acute Myocardial Infarction – Implications for Inflammatory Myocardial Damage

Atilla Yilmaz¹, Barbara Dietel², Iwona Cicha², Katja Schubert¹, Roland Hausmann³, Werner G. Daniel², Christoph D. Garlichs², Christian Stumpf²

¹Clinic of Internal Medicine I, Department of Cardiology, University Hospital Jena, Jena, Germany; ²Medical Clinic II, University Hospital Erlangen, Erlangen, Germany; ³Department of Forensic Medicine, University Basel, Switzerland

ABSTRACT

Dendritic cells (DC) are crucial for T cell mediated immune responses. Recently, we observed a significant decrease in circulating myeloid DC precursors in patients with acute myocardial infarction (AMI). The aim of the present study was to investigate whether myeloid DC are present in infarcted myocardium. Myocardial specimens of 10 patients with AMI and 7 accident victims (controls) were collected after autopsy. In immunostainings the presence of DC (CD209+, fascin+), T cells (CD3+), macrophages (CD68+), and HLA-DR expression was analyzed. Significantly higher numbers of CD209+–DC (97 vs. 44 cells/0.25 mm², p=0.03), fascin+–DC (54 vs. 8 cells/0.25 mm², p=0.02), T cells (27 vs. 6 cells/0.25 mm², p=0.02), and macrophages (44 vs. 6 cells/0.25 mm², p=0.01) associated with high HLA-DR expression were detected in infarcted myocardium. Frequent colocalizations of DC and T cells were observed. In occluded coronary arteries numerous DC, T cells, macrophages and high HLA-DR expression were found. We show that DC are present in infarcted myocardium after AMI. High HLA-DR expression and the colocalization with T cells suggest that they might trigger an immune response leading to further myocardial damage. (Int J Biomed Sci 2010; 6(1):27-36)

Keywords: adaptive immunity; atherosclerosis; innate immunity; leukocyte; dendritic cells

INTRODUCTION

The initial inflammatory response after acute myocardial infarction (AMI) is a prerequisite for healing and scar formation, whereas overwhelming and persisting myocardial inflammation is responsible for further destruction of vital myocardium promoting left ventricular (LV) remodelling and consecutively heart failure (1). Correspondingly, it was shown that elevated serum levels of pentraxin-3, high sensitivity (hs)CRP, and amyloid a are independent predictors of a worse outcome after AMI (2-4). However, therapeutic interventions using corticosteroids or nonsteroidal anti-inflammatory drugs to suppress myocardial inflammation failed to be effective to prevent LV remodelling after AMI, and were even associated with a higher incidence of infarct expansion and cardiac rupture (5, 6).

Beyond acute inflammation, it was described that immune reactions against cardiac contractile proteins such as actin, myosin, or troponin emerge after AMI, leading to persisting myocardial inflammation, which promotes LV remodelling and progressive heart failure (7, 8) Further
characterization of that immune reaction showed that the presence of Th1 cells is associated with a worse clinical outcome (9). In concordance with that, it was shown in animal models that suppression of the invasion of immune cells into the infarcted myocardium had a protective effect on LV remodelling after AMI (10, 11). These results suggest that autoimmunity may contribute to further myocardial damage after AMI.

Dendritic cells (DC) are potent antigen-presenting cells, required for the induction of each immune response through antigen-specific activation of T cells (12). In various autoimmune diseases, DC play a crucial role, inducing an immune response against self antigens (13). In atherosclerosis, it was assumed that DC contribute to progression and destabilization of atherosclerotic plaques (14). Proving this concept, Han et al. recently demonstrated in a vascular model that DC are the most potent T cell activators in atherosclerosis and are pivotal for the immune reactions in the vessel wall microenvironment (15).

In two recent studies, it was described that circulating DC precursors are significantly, transiently reduced in acute coronary syndromes (ACS) (16, 17). It was suggested that they might be recruited into the atherosclerotic vascular wall (16). However, the vast difference in the levels of circulating myeloid DC precursors between patients with unstable coronary artery disease (CAD) and those with ST segment elevation -AMI made it very likely that they might be additionally recruited into the infarcted myocardium (16).

Therefore, the aim of our present study was to investigate whether DC are present in the infarcted myocardium of patients with AMI, and if they are able to trigger there an immune response through antigen-specific activation of T cells.

METHODS

Patients and controls

In collaboration with the Department of Forensic Medicine of the University Hospital Erlangen myocardial specimens were collected from 10 individuals with AMI deceased after sudden cardiac death and 7 individuals after fatal accident as controls. Myocardial specimens were collected from the macroscopically evident infarction area and from corresponding areas of the controls. Histological analyses were performed using a haematoxylin/eosin staining (Figure 1). The diagnosis of an AMI was confirmed by macroscopical and microscopical evaluation, as described (18). Since patients died before admission in the hospital, we were not able to record clinical data. The study was carried out in accordance with the Declaration of Helsinki of the World Medical Association (19).

Immunohistochemical Analysis

For immunohistochemical staining, the following monoclonal antibodies were used: anti-CD209 (1:50; Becton Dickinson, Heidelberg, Germany) for immature and anti-fascin (1:100; Dako, Hamburg, Germany) for mature myeloid DC, anti-CD3 (1:80; Dako, Hamburg, Germany) for T cells, anti-CD68 (prediluted, Dako) for macrophages, and anti-HLA-DR (1:25; Dako). For immunohistochemical stainings of CD209, CD3, CD68, and HLA-DR the Catalyzed Signal Amplification kitTM (Dako) and for fascin staining the EnVision G/2 Detection System™ (Dako) were used according to manufacturer’s instructions. Double immunohistochemical staining was performed using the EnVisionTM Doublestain System (Dako) according to manufacturer’s instructions. Negative controls for single or double immunostainings were treated with isotype-matched antibodies (Figure 2A, 5A).

Stained cells were counted in the infarction area of AMI patients with a CCD-camera (Nikon DXM 1200, Düsseldorf, Germany) at a magnification of 150x in each five representative sections (each 0.25 μm²). For controls, corresponding areas were analyzed. For each patient, median cell numbers of CD209+ -DC, CD68+ macrophages, CD3+ -T cells, and HLA-DR+ -cells in the myocardium were calculated.

Statistical analysis

All values are reported as median. P<0.05 was considered statistically significant. The non-parametric Mann-Whitney Rank Sum Test was used to compare the median number of different immune cells between AMI patients and controls. Correlation analyses were performed using the Spearman Rank Order Test.

RESULTS

Emergence of DC, T cells and macrophages in infarcted myocardium

In the present study, we investigated if myeloid DC, which were shown to be significantly reduced in the circulation of patients with AMI, might be present in infarcted myocardium of patients deceased after sudden cardiac death. All patients in the AMI group had macroscopically and microscopically evident signs of myocardial infarction (Figure 1).
In infarcted myocardium, we observed significantly higher numbers of DC, detected by their specific expression of CD209 (97 vs. 44 cells / 0.25 mm$^2$, $p = 0.03$, Figure 2B) or fascin (54 vs. 8 cells / 0.25 mm$^2$, $p = 0.02$, Figure 2C), compared to healthy control myocardium. Furthermore, significantly more T cells (27 vs. 6 cells / 0.25 mm$^2$, $p = 0.02$, Figure 3A) and macrophages (44 vs. 6 cells / 0.25 mm$^2$, $P = 0.01$, Figure 3B) were observed in infarcted than in control myocardium. Associated with the presence of DC, macrophages, and T cells was a strong expression of HLA-DR (Figure 2 and 3).

**Significant correlation between different types of immune cells and HLA-DR**

The emergence of different types of immune cells and HLA-DR expression in the infarcted myocardium was compared by correlation analysis. We show a significant correlation between CD209$^+$-DC and HLA-DR-positive cells ($r = 0.48$, $p = 0.04$, Figure 4A). Additionally, a significant correlation between DC and T cells ($r = 0.58$, $p = 0.02$, Figure 4B) was observed. These results suggest that DC significantly contribute to HLA-DR expression and might be colocalized to T cells, so that all preconditions are fulfilled which are necessary for the induction of a DC-mediated immune response.

Furthermore, a significant correlation between DC and macrophages ($r = 0.83$, $p < 0.001$, Figure 4C) was detected, which is not surprising, since both myeloid DC and macrophages are monocyte-derived cells with a similar migratory pattern in response to inflammatory stimuli. Similar to DC, macrophages significantly correlated with T cells ($r = 0.78$, $p < 0.001$, Figure 4D), suggesting that they might contribute to T cell activation too.

**Colocalization of DC with T cells**

Beyond correlation analysis, the colocalization of DC with T cells was investigated in a more direct manner using
A. Negative controls

For CD 209, HLA-DR, CD 68, CD 3
For Fascin

B. Myeloid CD209+ DC

For CD 209, HLA-DR, CD 68, CD 3

C. Myeloid fascin+ DC

For CD 209, HLA-DR, CD 68, CD 3

Figure 2. Emergence of myeloid DC in infarcted myocardium. (A) Negative (isotype) controls for CD 209, HLA-DR, CD 3, and CD 68 (CSA immunostaining) as well as for fascin (Envision G/2 immunostaining) in control (left) and infarcted myocardium (right). (B, C) Identification of DC by the specific markers CD 209 (CSA, Becton Dickinson 1:50) and fascin (Envision G/2, Dako, 1:100), and corresponding expression of HLA-DR (CSA, Dako, 1:25) in control (left) and infarcted myocardium (right). Histographical presentation: box plot of the number of CD 209+ and fascin+ DC (cells/0.25 µm²) in control (CTL) and infarcted (AMI) myocardium. Statistical analysis by Mann–Whitney Rank Sum Test.
Figure 3. Presence of T cells and macrophages in infarcted myocardium. Images of immunostainings of (A) T cells (CSA, CD3+, Dako, 1:80) and (B) macrophages (CSA, Dako, CD68+, prediluted) together with HLA-DR expression (CSA, 1:25) in control (CTL) and infarcted (AMI) myocardium and corresponding histographical presentation. Statistical analysis by Mann–Whitney Rank Sum Test.
Correlation between DC, T cells, macrophages, and HLA-DR expression

**Figure 4.** Significant correlation between different types of immune cells and HLA-DR expression. Correlation analyses (Spearman Rank Order Test) were performed comparing the number of DC, T cells, macrophages, and HLA-DR⁺ cells to each other, which were evaluated by immunohistochemical stainings and subsequent digital image analysis. (A) Correlation between CD209⁺-DC and HLA-DR⁺ cells, (B) between CD209⁺-DC and CD3⁺ T cells, (C) between CD69⁺-macrophages and CD209⁺-DC, and (D) between CD69⁺-macrophages and CD3⁺ T cells. On both axis, the number of cells per 0.25 µm² is indicated.

double immunohistochemical staining. The proof of a colocalization of DC and T cells is pivotal, since the induction of a DC-initiated immune response is only possible, when both cell types have close physical contacts. In contrast to control, we were able to show numerous contacts between DC (CD209⁺ or fascin⁺) and T cells (CD3⁺) in infarcted myocardium, which exceeded by far the number of cell contacts expected by random distribution (Figure 5B). Hence, these results appear most consistent with the interpretation that DC may be directly activating T cells in infarcted myocardium.

**Emergence of different immune cells and HLA-DR in occluded coronary arteries**

Frequently, coronary arteries with thrombotical occlusions were observed in the myocardial specimens of patients with AMI. Compared to healthy vessels of controls, in thrombotically occluded coronaries a dense infiltration of all vascular layers with CD209⁺-DC, fascin⁺-DC, T cells, macrophages, and a high HLA-DR expression was observed (Figure 6), indicating a high coronary vascular inflammation. However, we were unable to determine
Control Myocardium

Infarcted Myocardium

A. Negative controls

![Control Myocardium](image1.png) ![Infarcted Myocardium](image2.png)

B. DC – T cell double immunostaining

**CD209 – CD3**

![CD209 – CD3](image3.png)

**Fascin – CD3**

![Fascin – CD3](image4.png)

**Figure 5.** Cell contacts between DC and T cells. Double immunohistochemical stainings (Envision TM Doublestain system, Dako) of CD209⁺-DC (brown, 1:50) vs. CD3⁺-T cells (red, 1:80) and fascin⁺-DC (brown, 1:100) vs. CD3⁺-T cells (red, 1:80) were performed to show cell contacts between DC and T cells. (A) Negative (isotype) controls and (B) control myocardium (left) compared to infarcted myocardium (right). Direct cell contacts are indicated by circles.
Coronary Vascular Inflammation

**Figure 6.** Emergence of different immune cells and HLA-DR in occluded coronaries. Immunohistochemical stainings (conditions see Figure 2) of CD209⁺-DC, fascin⁺-DC, CD3⁺-T cells, CD68⁺-macrophages, and high HLA-DR expression in a thrombotically occluded intramyocardial coronary artery.

whether coronary inflammation precedes, accompanies, or follows AMI.

**DISCUSSION**

Beyond acute inflammation upon AMI, a persisting autoimmune response against cardiac proteins emerges, which is responsible for further myocardial damage leading to progressive heart failure (20). Hence, it was shown that adoptive transfer of splenocytes of post-AMI rats into syngeneic rats was associated with organ specific autoimmune myocarditis (21). Furthermore, in blood of humans after AMI the presence of autoantibodies and cellular autoimmune against cardiac proteins was detected (7, 8). In this context, it was shown that in patients with AMI a Th1 response, present as high ratio of interferon-γ-producing blood T cells, persists over months. This enduring, overwhelming autoimmune response gets clinically apparent in some cases several weeks after AMI as Dressler’s syndrome (22).

DC play a pivotal role through initiating and modulating antigen-specific activation of T cells. It was shown that DC can be attracted into infarcted tissues such as brain, kidney and liver, and are able to induce an autoimmune response there (23-25). However, the role of DC in human AMI was unknown yet. Recently, we described that circulating myeloid DC precursors are significantly reduced in patients with AMI, indicating that they might be recruited into the infarcted myocardium (16). Thus, the aim of the present study was to investigate if myeloid DC might be present in human myocardium after AMI.

We show for the first time that DC infiltrate human infarcted myocardium of patients deceased after AMI. Con-
DENDRITIC CELLS AND ACUTE MYOCARDIAL INFARCTION

considering the fact that circulating myeloid DC precursors are significantly, transiently reduced in patients with AMI (16), it is most likely that upon AMI circulating DC precursors are recruited into the infarcted myocardium. Corresponding to this hypothesis, two third of the DC found in infarcted myocardium expressed an immature phenotype (CD 209 expression) compared to one third mature DC (fascin expression). This result is explained by the fact that the analysis was performed at a very early stage of AMI, since patients died very soon after onset of symptoms from sudden cardiac death, so that a maturation of DC, which endures several days, was not possible in this case. However, technical reasons, e.g. different staining procedures, can not be completely excluded.

Furthermore, numerous T cells and macrophages were detected in the infarcted myocardium, and they significantly correlated with the number of DC. This fact is very important because single DC are not able to mediate effects of the immune system, but the presence of further immune cells is required like an orchestra, so that DC can initiate an immune response. In the area of infarction a strong expression of HLA-DR, which significantly correlated with the presence of DC, was observed. Furthermore, direct cell contacts of DC and T cells were detected, so that it is very likely that DC induce an immune response to cardiac antigens leading to myocardial inflammation after AMI.

These results are consistent with former animal studies analyzing the recruitment of DC into the infarcted myocardium. Zhang et al. firstly described the presence of DC, associated with MHC II expression and T cell contacts, in the heart of rats with experimental AMI (26). More recently, Naito et al. demonstrated that GM-CSF and G-CSF inversely affected LV remodelling after experimental AMI, and they concluded that modulation of the immune response by myocardium-infiltrating DC is crucial for the development of progressive heart failure (27). Additionally, Takahashi et al. showed that locally injected high-mobility group box (HMGB)-1 significantly reduced the myocardial infiltration of DC after AMI, and, thus, improved global cardiac function (28).

Beyond myocardial inflammation, we showed significant inflammation of occluded coronary arteries. However, coronary vascular inflammation might be the reason or the result of AMI, which can not be determined in the present study. Recently, it was shown that platelets induce vascular recruitment and maturation of DC (29). Hence, interaction of platelets with DC might be the link between thrombosis and coronary inflammation.

CONCLUSIONS

The results of our study show that infarcted myocardium is significantly infiltrated with DC, macrophages, and T cells. The high expression of HLA-DR and frequent contacts with T cells indicate that DC initiate an immune response against cardiac antigens in the infarcted myocardium leading to progressive heart failure. Thus, modulation of DC function might be a novel therapeutic approach to prevent LV remodelling after AMI.

REFERENCES

1. Frangogiannis NG, Smith CW, Entman ML. The inflammatory response in myocardial infarction. Cardiovasc. Res. 2002; 53 (1): 31-47.
2. Latini R, Maggioni AP, Peri G, Gonzini L, et al. Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. Circulation. 2004; 110 (16): 2349-2354.
3. Berton G, Cordiano R, Palmieri R, Pianca S, et al. C-reactive protein in acute myocardial infarction: association with heart failure. Am. Heart J. 2003; 145 (6): 1094-1101.
4. Katayama T, Nakashima H, Takagi C, Honda Y, et al. Serum amyloid a protein as a predictor of cardiac rupture in acute myocardial infarction patients following primary coronary angioplasty. Circ. J. 2006; 70 (5): 530-535.
5. Roberts R, DeMello V, Sobel BE. Deleterious effects of methylprednisolone in patients with myocardial infarction. Circulation. 1976; 53 (3 Suppl): 1204-206.
6. Brown EJ Jr., Kloner RA, Schoen FJ, Hammerman H, et al. Scar thinning due to ibuprofen administration after experimental myocardial infarction. Am. J. Cardiol. 1983; 51 (5): 877-883.
7. Eriksson S, Hellman J, Petersson K. Autoantibodies against cardiac troponins. N. Engl. J. Med. 2005; 352 (1): 98-100.
8. Moraru M, Roth A, Keren G, George J. Cellular autoimmunity to cardiac myosin in patients with a recent myocardial infarction. Int. J. Cardiol. 2006; 107 (1): 61-66.
9. Cheng X, Liao YH, Ge H, Li B, et al. TH1/TH2 functional imbalance after acute myocardial infarction: coronary arterial inflammation or myocardial inflammation. J. Clin. Immunol. 2005; 25 (3): 246-253.
10. Hayashidani S, Tsutsui H, Shiomi T, Ikeuchi M, et al. Anti-monocyte chemoattractant protein-1 gene therapy attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation. 2003; 108 (17): 2134-2140.
11. Kaikita K, Hayasaki T, Okuma T, Kuziel WA, et al. Targeted deletion of CC chemokine receptor 2 attenuates left ventricular remodeling after experimental myocardial infarction. Am. J. Pathol. 2004; 165 (2): 439-447.
12. Banchereau J, Briere F, Caux C, Davoust J, et al. Immunobiology of dendritic cells. Annu. Rev. Immunol. 2000; 18: 767-811.
13. Cravens PD, Lipsky PE. Dendritic cells, chemokine receptors and autoimmune inflammatory diseases. Immunol. Cell Biol. 2002; 80 (5): 497-505.
14. Yılmaz A, Lochno M, Traeg F, Cicha I, et al. Emergence of dendritic cells in rupture-prone regions of vulnerable carotid plaques. Atherosclerosis. 2004; 176 (1): 101-110.
cular inflammation. *Circ. Res.* 2008; 102 (5): 546-553.
16. Yilmaz A, Weber J, Cicha I, Stumpf C, *et al.* Decrease in circulating myeloid dendritic cell precursors in coronary artery disease. *J. Am. Coll. Cardiol.* 2006; 48 (1): 70-80.
17. Van Vre EA, Hoymans VY, Bult H, Lenjou M, *et al.* Decreased number of circulating plasmacytoid dendritic cells in patients with atherosclerotic coronary artery disease. *Coron. Artery. Dis.* 2006; 17 (3): 243-248.
18. The pathological diagnosis of acute myocardial infarction: preliminary results of a WHO cooperative study. *Bull World Health Organ.* 1973; 48 (1): 23-25.
19. World Medical Association Declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. *Cardiovasc. Res.* 1997; 35 (1): 2-3.
20. Liao YH, Cheng X. Autoimmunity in myocardial infarction. *Int. J. Cardiol.* 2006; 112 (1): 21-26.
21. Maisel A, Cesario D, Baird S, Rehman J, *et al.* Experimental autoimmune myocarditis produced by adoptive transfer of splenocytes after myocardial infarction. *Circ. Res.* 1998; 82 (4): 458-463.
22. De Scheerder I, Vandekerckhove J, Robbrecht J, Algoed L, *et al.* Post-cardiac injury syndrome and an increased humoral immune response against the major contractile proteins (actin and myosin). *Am. J. Cardiol.* 1985; 56 (10): 631-633.
23. Costulas N, Li HL, Xiao BG, Huang YM, *et al.* Dendritic cells are present in ischemic brain after permanent middle cerebral artery occlusion in the rat. *Stroke.* 2002; 33 (4): 1129-1134.
24. Kim BS, Lim SW, Li C, Kim JS, *et al.* Ischemia-reperfusion injury activates innate immunity in rat kidneys. *Transplantation.* 2005; 79 (10): 1370-1377.
25. Tsung A, Zheng N, Jeyabalann G, Izuishi K, *et al.* Increasing numbers of hepatic dendritic cells promote HMGB1-mediated ischemia-reperfusion injury. *J. Leukoc. Biol.* 2007; 81 (1): 119-128.
26. Zhang J, Yu ZX, Fujita S, Yamaguchi ML, *et al.* Interstitial dendritic cells of the rat heart. Quantitative and ultrastructural changes in experimental myocardial infarction. *Circulation.* 1993; 87 (3): 909-920.
27. Naito K, Anzai T, Sugano Y, Maekawa Y, *et al.* Differential effects of GM-CSF and G-CSF on infiltration of dendritic cells during early left ventricular remodeling after myocardial infarction. *J. Immunol.* 2008; 181 (8): 5691-5701.
28. Takahashi K, Fukushima S, Yamahara K, Yashiro K, *et al.* Modulated inflammation by injection of high-mobility group box 1 recovers post-infarction chronically failing heart. *Circulation.* 2008; 118 (14 Suppl): SI06-114.
29. Langer HF, Daub K, Braun G, Schonberger T, *et al.* Platelets recruit human dendritic cells via Mac-1/JAM-C interaction and modulate dendritic cell function in vitro. *Arterioscler. Thromb. Vasc. Biol.* 2007; 27 (6): 1463-1470.